Radiopharmaceutical-related pitfalls and artifacts
References (465)
- et al.
Inorganic tin: chemistry, disposition and role in nuclear medicine diagnostic skeletal imaging agents
Int J Nucl Med Biol
(1981) - et al.
Radionuclide-labeled red blood cells: current status and future prospects
- et al.
99mTc bone scanning agents—V. Influence of experimental conditions on the labeling efficiency and gel chromatography of 99mTc(Sn)HMDP
Nucl Med Biol
(1987) - et al.
Studies on some aspects of the instability of Tc-hexamethylpropylene amine oxime (Tc-HMPAO)
Nucl Med Biol
(1993) - et al.
The influence of the method of preparation of the bone scanning agent 99mTc(Sn)EHDP on its tissue distribution in the rat
Int J Appl Radiat Isot
(1982) - et al.
Labelling of leukocytes with 99mTc-HMPAO for scintigraphy of inflammatory lesions and abscesses
Nucl Med Biol
(1992) - et al.
Effect of granulocyte concentration on leukocyte labelling efficiency with 99mTc-HMPAO
Nucl Med Biol
(1990) - et al.
Iatrogenic alterations in the biodistribution of radiotracers as a result of drug therapy: Reported instances
- et al.
Iatrogenic alterations in the biodistribution of radiotracers as a result of radiation therapy, surgery, and other invasive medical procedures
- et al.
Normal clinical variation in anatomic structure and physiologic function and its effect on radiopharmaceutical biodistribution
Unusual or unanticipated alterations in the biodistribution of radiopharmaceuticals as a result of pathologic mechanisms
Clinical manifestations of radiopharmaceutical formulation problems
A review of radiopharmaceutical formulation problems and their clinical manifestations
Factors which affect the integrity of radiopharmaceuticals
Technetium-99m d,l-HM-PAO: A new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion
J Nucl Med
(1987)
Kit preparation of technetium-99m-mercaptoacetyltriglycine: Analysis, biodistribution and comparison with technetium-99m-DTPA in patients with impaired renal function
J Nucl Med
(1990)
Failure of quality control to detect errors in the preparation of technetium-99mdisofenin (DISIDA)
Clin Nucl Med
(1985)
Unit dose radiochemical stability of commonly used technetium-99m radiopharmaceuticals
J Nucl Med Technol
(1986)
Artifactual focal accumulation of Tc-99m bone imaging tracer in the chest
Clin Nucl Med
(1985)
Quality control of Tc-99m DTPA used for GFR studies
J Nucl Med
(1988)
Quality control of technetium-99m DTPA: Correlation of analytic tests with in vivo protein binding in man
J Nucl Med
(1986)
Diffuse thoracoabdominal radioactivity seen in bone imaging
Clin Nucl Med
(1986)
Generator-produced 99mTcO4 carrier-free?
J Nucl Med
(1975)
The current status of 99mTc generators
Nuklearmedizin
(1981)
Free (unreacted) pertechnetate in technetium-sulfur colloid preparations
J Nucl Med Technol
(1974)
Chemistry of technetium radiopharmaceuticals. I. Exploration of the tissue distribution and oxidation state consequences of technetium (IV) in Tc-Sn-gluconate and Tc-Sn-EHDP using carrier 99Tc
J Nucl Med
(1975)
The effect of carrier technetium in the preparation of 99mTc-human serum albumin
J Nucl Med
(1976)
Poor binding efficiency using 99Tcm-labeled HSA
Nucl Med Commun
(1990)
Chemical effect of 99Tc on 99mTc labeled radiopharmaceuticals
J Nucl Med
(1975)
A simple kit for the preparation of 99mTc-labeled red blood cells
J Nucl Med
(1976)
Acid-citratedextrose compared with heparin in the preparation of in vivo/in vitro technetium-99m red blood cells
J Nucl Med
(1983)
Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with UltraTag® RBC kit
J Nucl Med
(1992)
Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with UltraTag® RBC kit—Reply
J Nucl Med
(1992)
Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with UltraTag® RBC kit—Reply
J Nucl Med
(1992)
An assessment of factors which influence the effectiveness of the modified in vivo erythrocyte labeling technique
J Nucl Med
(1991)
An assessment of factors which influence the effectiveness of the modified in vivo technetium-99m-erythrocyte labeling technique in clinical use
J Nucl Med
(1992)
UltraTag® RBC kit—Relationship between anticoagulants and reagent volume on RBC labeling efficiency and kinetics
J Nucl Med
(1992)
Optimum concentration of ACD in the preparation of technetium-99m red blood cells with the UltraTag® RBC kit
J Nucl Med Technol
(1992)
Determination of brain death with technetium-99m-HMPAO
J Nucl Med
(1990)
Labelling efficiency analysis of 99mTc-HMPAO: Comparison between standard elution and multiple elution method
J Nucl Med
(1991)
Radiochemical purity of technetium-99m-HMPAO depends on specific activity
J Nucl Med
(1995)
Effect of chemical and radiochemical impurities from eluants on 99mTc-labeling efficiency
Nuklearmedizin
(1977)
Failure of labeling of anti-granulocyte antibody
Eur J Nucl Med
(1993)
Technetium-99m MAG3: Labeling conditions and quality control
J Nucl Med Technol
(1993)
Effects of generator eluate age on the radiochemical purity of fractionated 99Tcm-MAG3
Nucl Med Commun
(1995)
Generator eluate effects on the labeling efficiency of Tc-99m sestamibi kits
J Nucl Med
(1993)
Radiopharmaceutical factors in the variable quality of [99mTc] HMPAO images
J Nucl Med
(1990)
Use of sodium iodide to overcome the eluate age restriction for Ceretec™ reconstitution
Nucl Med Commun
(1989)
A routine method for using sodium iodide to stabilize sodium pertechnetate [99Tcm] dispensed for the preparation of 99Tcm-exametazime
Nucl Med Commun
(1992)
Cited by (51)
Pitfalls and limitations of SPECT, PET, and therapeutic radiopharmaceuticals
2015, Seminars in Nuclear MedicineExtravasation of radiopharmaceuticals: Preventive measures and management recommended by SoFRa (Société Française de Radiopharmacie)
2013, Annales Pharmaceutiques FrancaisesAltered Biodistribution of Radiopharmaceuticals: Role of Radiochemical/Pharmaceutical Purity, Physiological, and Pharmacologic Factors
2010, Seminars in Nuclear MedicineCitation Excerpt :Even at very low concentrations (1.0 μg/mL), Al3+ reacts with phosphate buffer and forms insoluble aluminum phosphate.27 99mTc-SC coprecipitates with aluminum phosphate and the flocculated particles are trapped in the lung capillaries.3 At higher concentrations (>10 μg/mL), Al3+ may react with 99mTc-MDP forming insoluble particles, which are taken up by the cells of RES in liver (Fig. 2) and spleen.28
Ring sign over left kidney in <sup>99m</sup>Tc DTPA renal scintigraphy
2010, Revista Espanola de Medicina NuclearRadiopharmaceutical considerations for using Tc-99m MAA in lung transplant patients
2010, Journal of the American Pharmacists AssociationNonosseous bone seeking tracer focal uptake in the conventional scintigraphy
2023, Nuklearmedizin - NuclearMedicine
Copyright © 1996 Published by Elsevier Inc.